Discover
IOBT
IO Biotech, Inc.
0.05
1 x 0.04
6 x 0.04
bid
ask
+
0.00
0.00%
4 @ 04:00 PM
0.05 +0.01 (13.75%)
| Ytd | -92.12% | |
| 1y | -97.00% |
0.03
day range
0.06
0.66
52 week range
2.10
| Open | 0.03 | Prev Close | 0.05 | Low | 0.03 | High | 0.06 | Mkt Cap | 58.61M |
| Vol | 469.19M | Avg Vol | 347.79K | EPS | -1.29 | P/E | N/A | Forward P/E | -0.76 |
| Beta | 0.42 | Short Ratio | 1.89 | Inst. Own | 76.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 0.99 | 200-d Avg | 1.26 | 1yr Est | 9.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.29 | -0.36 | -0.07 | -24.14% |
| 2024-08-13 | 2024-06 | -0.34 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -0.34 | -0.31 | 0.03 | 8.82% |
| 2024-05-14 | 2024-03 | -0.37 | -0.3 | 0.07 | 18.92% |
| 2024-05-14 | 2024-03 | -0.37 | N/A | N/A | N/A |
| 2024-03-05 | 2023-12 | -0.36 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-16 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2024-09-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-03 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-09-03 | Morgan Stanley | Upgrade | Overweight | Overweight |
Profile
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-11-21 | BURKAVAGE BRIAN | Officer | 11.50K | Purchase |
| 2023-08-08 | ELLING CHRISTIAN E. PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2023-08-08 | LUNDBECKFOND INVEST AS | Beneficial Owner of more than 10% of a Class of Security | 13.95M | Stock Award(Grant) |
| 2024-07-25 | NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | 4.35M | Sale |
| 2023-08-08 | SMITH DEVIN WHITTEMORE | General Counsel | 4.94K | Stock Award(Grant) |
| 2023-08-08 | SULLIVAN AMY B. | Chief Financial Officer | 74.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vivo Capital, LLC | 6.17M | 5.49M | 9.37% |
| 2024-09-29 | Samsara BioCapital, LLC | 3.64M | 3.24M | 5.53% |
| 2024-09-29 | Novo Holdings A/S | 3.35M | 2.98M | 5.09% |
| 2024-09-29 | Pfm Health Sciences, Lp | 2.34M | 2.08M | 3.55% |
| 2024-09-29 | Morgan Stanley | 2.20M | 1.96M | 3.34% |
| 2024-09-29 | Marshall Wace LLP | 2.11M | 1.87M | 3.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 199.00K | 177.03K | 0.30% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 33.31K | 29.63K | 0.05% |